Compliance & Policy

China's Export Controls Freeze 14 Technologies, License 26 More

Announcement [2026] No. 48 puts 40 AI, solar and biotech technologies under interim pre-export registration from November 16, 2026, banning 14 outright and licensing 26 before final codification in early 2027.

China Enforces Interim Registration on 40 AI, Solar and Biotech Export-Control Technologies
China Enforces Interim Registration on 40 AI, Solar and Biotech Export-Control TechnologiesQuanlecntt2004 / pixabay

Waypoints

  1. Interim pre-export registration took effect November 16, 2026 for 40 technologies under Announcement [2026] No. 48.

  2. 14 technologies face an absolute export ban, including monocrystalline ingot casting and proprietary wafer slicing; 26 require licensing.

  3. 12 of the 40 items target photovoltaic manufacturing: polysilicon crystallization, wafer slicing and high-efficiency solar cells.

  4. AI models with compute of 10²⁶ FLOPs, 2 trillion parameters or top-10 benchmark ranking enter the restricted tier.

  5. Final Catalogue promulgation is expected in early 2027; deals initiated before October 16, 2026 need retroactive registration.

Forty technologies — 23 in artificial intelligence, 12 in photovoltaic manufacturing and 5 in biomanufacturing — fell under immediate interim pre-export registration in China on November 16, 2026, one day after public consultation closed on Announcement [2026] No. 48. The Ministry of Commerce and the Ministry of Science and Technology jointly promulgated the measure under Article 20 of the Foreign Trade Law and the Regulations on Technology Import and Export Administration, updating the Catalogue of Technologies Prohibited or Restricted from Export before final codification, which authorities expect in early 2027.

For the solar supply chain, the headline number is twelve. Of the 40 proposed items, 12 target photovoltaic manufacturing: polysilicon crystallization, wafer slicing and high-efficiency solar cell processes. An absolute export ban applies to monocrystalline ingot casting and proprietary wafer slicing processes; the remaining items sit in the restricted tier, subject to licensing with product-specific carve-outs and automatic licensing for transactions that do not transfer ownership.

How does the two-tier system work?

Regulators split the 40 technologies into two legal tiers. Fourteen are prohibited outright, meaning an absolute ban on cross-border transfer. Twenty-six are restricted and require administrative licensing review.

On the AI side, restricted status attaches when a large language model meets any of three quantitative tests: training compute of 10²⁶ FLOPs or more, 2 trillion parameters or more, or top-10 performance on recognized public benchmarks. Restrictions then cover model weights, training checkpoints, architecture design documents and optimization know-how. Prohibited AI items include models trained on state "core data," offensive cyber tools, and defense or critical infrastructure agents.

The thresholds drew comment. Analysts at the Cloud Security Alliance noted that the 10²⁶ FLOPs compute threshold aligns with international safety evaluation benchmarks, and said that separating API-based service access from localized weight deployments "offers vital operational clarity" for multinational software ecosystems, so long as model custody remains on domestic Chinese servers.

What counts as an export?

Not everything with a border crossing. Technologies already in the public domain through open-source releases or peer-reviewed literature are expressly excluded. MOFCOM also clarified that remote access via APIs, SaaS portals, mobile applications or on-device runtimes does not constitute an export. An export occurs only when weights, code or custodial infrastructure are physically transferred or deployed on foreign infrastructure.

Biomanufacturing carries its own distinction. The prohibition applies only to outbound assignments of intellectual property ownership over reusable foundational platforms — cell and gene therapies, small nucleic acid platforms and pathogen genetic modification methods. Product-specific out-licensing of drug candidates remains eligible for streamlined review and prospective automatic licensing, provided platform IP stays domiciled in China.

What do the lawyers say?

Baker McKenzie observed that interim registration creates an enforceable compliance obligation before the final Catalogue becomes law. Registration is not approval, but transferring controlled code, data or technical assistance without a pre-export filing exposes institutions to administrative penalties under Chinese foreign trade law.

Morgan Lewis advised multinational pharmaceutical developers to run immediate portfolio reviews and structure deals as product-specific grants rather than platform acquisitions. Pillsbury Winthrop Shaw Pittman warned the rules reach beyond conventional sales: mergers, equity acquisitions or restructurings that give a foreign entity actual control over a domestic Chinese holder of controlled technologies count as an export event requiring pre-closing registration with provincial commerce bureaus.

What must universities and joint institutes do?

The obligations land directly on international research universities, Sino-foreign cooperative institutes and technology-transfer offices. Open publishing remains exempt, but collaborative laboratory work involving unpublished model checkpoints, training datasets or proprietary biological screening assays falls squarely within the registration perimeter.

Four operational triggers require filing on the MOFCOM portal: outbound assignment of IP ownership; licensing domestic technology for overseas use; corporate changes shifting ownership or control of domestic IP to a foreign entity; and specific directives from commerce authorities. Transactions initiated before October 16, 2026 but not yet concluded must complete retroactive registration before closing. Filings go through the MOFCOM Unified Business Platform (ecomp.mofcom.gov.cn) with institutional data, foreign recipient identification, end-use documentation, technical parameters and projected valuations.

The revision is the most substantial structural change to China's technology export controls since August 2020, when the Catalogue — established in 2001, revised in 2008 and 2020 — last gained items such as recommendation algorithms and speech synthesis. The next milestone is formal promulgation of the revised Catalogue, expected in early 2027.

via casrai.org (Source)

Share this article:

More from Olivia Hart

Olivia Hart

Show full bio

Staff writer covering regulation, policy and their impact on Circular economy and the environmental industry at Circular Wire.

557 articles

Nearby routes

« Previous article